Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease
Calcified Tissue International · 2024
DOI: 10.1007/s00223-024-01187-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Calcified Tissue International, 2024. Verfasst von Wenjie Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Center of Breast and Thyroid Surgery, Department of General Surgery, The Third People's Hospital of Chengdu and The Affiliated Hospital of Southw…. Hauptthemen laut MEDLINE: Hyperphosphatemia, Hyperparathyroidism, Secondary, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
The study addresses the challenge of treating secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, focusing on the cost-effectiveness of surgical versus pharmacological interventions. Conducting a retrospective analysis on 152 CKD patients with SHPT at the Third People's Hospital of Chengdu, the study matched 80 patients into two groups: 40 undergoing parathyroidectomy with autotransplantation (PTX + AT) and 40 treated with calcimimetics. PTX + AT was more effective in alleviating symptoms, particularly bodily pain, and demonstrated greater cost-effectiveness over a long-term period compared to calcimimetics. This was especially significant in patients with PTH levels > 1800 pg/mL and hyperphosphatemia. Despite similar initial costs, PTX + AT led to a substantial decrease in expenses during the 2-5 years post-treatment period, PTX + AT results in an ICER of -RMB 26.71/QALY for the first post-treatment year and -RMB-111.9k/QALY for the 2-5 year period, indicating cost-effectiveness with reduced long-term costs. The study also found an increased economic burden in managing patients with hyperphosphatemia. Surgical intervention (PTX + AT) is advocated as the primary treatment strategy for severe SHPT in CKD patients, owing to its long-term economic and clinical advantages. The results underscore the need for a severity-based approach in treating SHPT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center of Breast and Thyroid Surgery, Department of General Surgery, The Third People's Hospital of Chengdu and The Affiliated Hospital of Southwest Jiaotong University, No. 19 Yangshi Road, Chengdu, 610031, China.
- Department of Gastrointestinal, Bariatric and Metabolic Surgery, and Research Center for Nutrition, Metabolism and Food Safety, West China School of Public Health and West China Fourth Hospital, West China-PUMC CC.C. Ch…
- Department of Laboratory Medicine, Chengdu First People's Hospital, Chengdu, 610041, Sichuan, China.
- The Center of Breast and Thyroid Surgery, Department of General Surgery, The Third People's Hospital of Chengdu and The Affiliated Hospital of Southwest Jiaotong University, No. 19 Yangshi Road, Chengdu, 610031, China.…
Zitieren
APA
Zhang, W., Ren, H., Liao, Q., & Wu, J. (2024). Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease. Calcified Tissue International. https://doi.org/10.1007/s00223-024-01187-3
Vancouver
Zhang W, Ren H, Liao Q, Wu J. Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease. Calcified Tissue International. 2024. doi:10.1007/s00223-024-01187-3
BibTeX
@article{Zhang2024,
author = {Zhang, Wenjie and Ren, Hailiang and Liao, Qianxiu and Wu, Jian},
title = {Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease},
journal = {Calcified Tissue International},
year = {2024},
doi = {10.1007/s00223-024-01187-3}
}
EUVIMED